Sun Pharma.Inds.

{
  "main_header": {
    "sid": 948699,
    "name": "Sun Pharma.Inds.",
    "stock_name": "Sun Pharma.Inds.",
    "full_name": "Sun Pharmaceutical Industries Ltd",
    "name_url": "stocks-analysis/sun-pharmainds",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,868.00",
    "chg": 32.5,
    "chgp": "1.77%",
    "dir": 1,
    "prev_price": "1,835.50",
    "mcapval": "450,595.00 Cr",
    "mcap": "Large Cap",
    "scripcode": 524715,
    "symbol": "SUNPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE044A01036",
    "curr_date": "Sep 21, 03:30 PM",
    "curr_time": "17:50 PM",
    "last_traded_at": "Sep 21, 03:30 PM IST",
    "bse_nse_vol": "25.99 lacs",
    "exc_status": "Active",
    "traded_date": "Sep 21, 2026",
    "traded_date_str": "2026 09 21",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sun-pharmainds-948699-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "6,089 Put Contracts at Rs 1,860 Strike Signal Protective Hedging in Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-heavy-put-option-activity-ahead-of-september-expiry-4199925",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/SunPharmaceutic_most_active_stocks_puts_4199925.png",
        "date": "2026-09-21 11:00:10",
        "description": "Rs 1,860 put options on Sun Pharmaceutical Industries Ltd attracted 6,089 contracts on 21 Sep 2026, while the stock traded at Rs 1,885.3. This out-of-the-money put activity, combined with a 2.42% daily gain and strong delivery volumes, suggests a protective hedging strategy rather than outright bearish positioning."
      },
      {
        "title": "15,402 Call Contracts on Sun Pharmaceutical Industries Ltd Signal Strong Directional Positioning Ahead of 29-Sep Expiry",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-surge-in-call-option-activity-ahead-of-september-expiry-4199926",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/SunPharmaceutic_most_active_stocks_calls_4199926.png",
        "date": "2026-09-21 11:00:08",
        "description": "On 21 Sep 2026, Sun Pharmaceutical Industries Ltd witnessed robust call option activity with 15,402 contracts traded at the Rs 1,900 strike price, while the stock closed at Rs 1,885, just below this level. This surge in call buying coincided with a 2.42% gain in the cash market, signalling a clear directional interest ahead of the 29 Sep expiry."
      },
      {
        "title": "P/E at 34.86 vs Industry's 37.18: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4199313",
        "imagepath": "",
        "date": "2026-09-21 09:21:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: A Slight Discount in a Premium Sector</strong></p>\n                <p>The current P/E of 34.86 for <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> is approximately 6.2% below the industry average of 37.18. While the sector is characterised by elevated valuations reflecting growth expectations and innovation pipelines, this discount suggests a more cautious market stance on the stock relative to peers. This valuation gap may reflect concerns over recent operational challenges or competitive pressures, but it also indicates that the stock is not trading at an excessive premium. <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharma<..."
      },
      {
        "title": "P/E at 35.44 vs Industry's 36.93: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4196928",
        "imagepath": "",
        "date": "2026-09-18 09:20:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Slight Discount in a High-P/E Sector</strong></p>\n                <p>The pharmaceutical and biotechnology sector currently exhibits a relatively elevated valuation environment, with an industry P/E of 36.93. Against this backdrop, <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> trades at a P/E of 35.44, representing a modest discount of approximately 4%. This suggests that the market is pricing in earnings growth or risk factors slightly less aggressively for the company compared to its peers. The premium or discount relative to sector P/E often reflects investor sentiment on growth prospects, regulatory risks, or competitive positioning. In this case, the near-parity valuation..."
      },
      {
        "title": "P/E at 35.2 vs Industry's 36.44: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-amid-market-dynamics-4195883",
        "imagepath": "",
        "date": "2026-09-17 09:21:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Slight Discount in a High-P/E Sector</strong></p>\n                <p>The pharmaceutical and biotechnology sector currently trades at an average P/E of 36.44, reflecting elevated valuations driven by growth expectations and innovation pipelines. Against this backdrop, <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a>’s P/E of 35.2 represents a modest discount of approximately 3.4%. This suggests that the market is pricing in slightly more conservative earnings growth or risk factors relative to its peers. The company’s large-cap status, with a market capitalisation of ₹4,44,717 crore, supports its premium valuation compared to smaller sector constituents, but the discount relative..."
      },
      {
        "title": "P/E at 34.85 vs Industry's 36.52: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-and-institutional-shifts-4194623",
        "imagepath": "",
        "date": "2026-09-16 09:21:03",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: A Slight Discount in a High-P/E Sector</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> trades at a P/E of 34.85, which is approximately 4.6% below the Pharmaceuticals & Biotechnology industry average of 36.52. This valuation gap suggests that the market is pricing the stock with a slight discount relative to its peers, despite its large-cap status and established market presence. The sector itself commands a premium valuation, reflecting growth expectations and defensive qualities amid market volatility. The stock’s P/E positioning may imply cautious optimism or reflect recent performance trends — <a href=\"https://www.marketsmojo.com/stocks-analy..."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sun-pharmaceutical-industries-ltd-is-rated-hold-4193263",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/SunPharmaceutic_mojoScore_4193263.png",
        "date": "2026-09-15 10:10:51",
        "description": "Sun Pharmaceutical Industries Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 03 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "P/E at 34.98 vs Industry's 37.05: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-market-dynamics-as-a-nifty-50-constituent-4192887",
        "imagepath": "",
        "date": "2026-09-15 09:21:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index confers considerable prestige and market influence on Sun Pharmaceutical Industries Ltd. This membership not only reflects the company’s substantial market capitalisation—currently standing at ₹4,41,958 crores, categorising it firmly as a large-cap stock—but also ensures heightened visibility among domestic and global investors. Index inclusion typically drives consistent demand from passive funds and exchange-traded funds (ETFs) tracking the Nifty 50, thereby supporting liquidity and price stability.</p>\n                <p>Sun Pharma’s position within this elite group also means its stock movements can significantly impact the overall index performance, especially given the Ph..."
      },
      {
        "title": "P/E at 35.4 vs Industry's 37.05: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-amidst-market-headwinds-4189991",
        "imagepath": "",
        "date": "2026-09-11 09:21:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: A Slight Discount in a High-P/E Sector</strong></p>\n                <p>The pharmaceutical sector currently trades at an average P/E of 37.05, reflecting elevated investor expectations amid ongoing innovation and regulatory approvals. Against this backdrop, <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a>’s P/E of 35.4 represents a 4.5% discount to the sector average. This valuation gap is relatively narrow but noteworthy given the company’s large-cap status and market leadership. The premium or discount relative to peers often signals market sentiment about growth prospects and risk profile — <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"..."
      }
    ],
    "total": 1279,
    "sid": "948699",
    "stock_news_url": "https://www.marketsmojo.com/news/sun-pharmaceutical-industries-948699"
  },
  "announcements": [
    {
      "caption": "Intimation Under Regulation 30 Of SEBI LODR",
      "datetime": "11-Sep-2026",
      "details": "As attached",
      "source": "BSE"
    },
    {
      "caption": "Incorporation Of A Subsidiary Company",
      "datetime": "09-Sep-2026",
      "details": "Incorporation of wholly owned subsidiary of the Company in the International Financial Services Centre at GIFT City Gandhinagar Gujarat India",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
      "datetime": "08-Sep-2026",
      "details": "International Credit Ratings",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has declared <strong>500%</strong> dividend, ex-date: 07 Jul 26",
          "dt": "2026-07-07",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:5</strong> stock split, ex-date: 25 Nov 10",
          "dt": "2010-11-25",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 29 Jul 13",
          "dt": "2013-07-29",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

6,089 Put Contracts at Rs 1,860 Strike Signal Protective Hedging in Sun Pharmaceutical Industries Ltd

2026-09-21 11:00:10

Rs 1,860 put options on Sun Pharmaceutical Industries Ltd attracted 6,089 contracts on 21 Sep 2026, while the stock traded at Rs 1,885.3. This out-of-the-money put activity, combined with a 2.42% daily gain and strong delivery volumes, suggests a protective hedging strategy rather than outright bearish positioning.

Read full news article

15,402 Call Contracts on Sun Pharmaceutical Industries Ltd Signal Strong Directional Positioning Ahead of 29-Sep Expiry

2026-09-21 11:00:08

On 21 Sep 2026, Sun Pharmaceutical Industries Ltd witnessed robust call option activity with 15,402 contracts traded at the Rs 1,900 strike price, while the stock closed at Rs 1,885, just below this level. This surge in call buying coincided with a 2.42% gain in the cash market, signalling a clear directional interest ahead of the 29 Sep expiry.

Read full news article

P/E at 34.86 vs Industry's 37.18: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-09-21 09:21:09

Valuation Picture: A Slight Discount in a Premium Sector

The current P/E of 34.86 for Sun Pharmaceutical Industries Ltd is approximately 6.2% below the industry average of 37.18. While the sector is characterised by elevated valuations reflecting growth expectations and innovation pipelines, this discount suggests a more cautious market stance on the stock relative to peers. This valuation gap may reflect concerns over recent operational challenges or competitive pressures, but it also indicates that the stock is not trading at an excessive premium. Sun Pharma<...

Read full news article

P/E at 35.44 vs Industry's 36.93: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-09-18 09:20:55

Valuation Picture: Slight Discount in a High-P/E Sector

The pharmaceutical and biotechnology sector currently exhibits a relatively elevated valuation environment, with an industry P/E of 36.93. Against this backdrop, Sun Pharmaceutical Industries Ltd trades at a P/E of 35.44, representing a modest discount of approximately 4%. This suggests that the market is pricing in earnings growth or risk factors slightly less aggressively for the company compared to its peers. The premium or discount relative to sector P/E often reflects investor sentiment on growth prospects, regulatory risks, or competitive positioning. In this case, the near-parity valuation...

Read full news article

P/E at 35.2 vs Industry's 36.44: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-09-17 09:21:09

Valuation Picture: Slight Discount in a High-P/E Sector

The pharmaceutical and biotechnology sector currently trades at an average P/E of 36.44, reflecting elevated valuations driven by growth expectations and innovation pipelines. Against this backdrop, Sun Pharmaceutical Industries Ltd’s P/E of 35.2 represents a modest discount of approximately 3.4%. This suggests that the market is pricing in slightly more conservative earnings growth or risk factors relative to its peers. The company’s large-cap status, with a market capitalisation of ₹4,44,717 crore, supports its premium valuation compared to smaller sector constituents, but the discount relative...

Read full news article

P/E at 34.85 vs Industry's 36.52: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-09-16 09:21:03

Valuation Picture: A Slight Discount in a High-P/E Sector

Sun Pharmaceutical Industries Ltd trades at a P/E of 34.85, which is approximately 4.6% below the Pharmaceuticals & Biotechnology industry average of 36.52. This valuation gap suggests that the market is pricing the stock with a slight discount relative to its peers, despite its large-cap status and established market presence. The sector itself commands a premium valuation, reflecting growth expectations and defensive qualities amid market volatility. The stock’s P/E positioning may imply cautious optimism or reflect recent performance trends — Read full news article

Sun Pharmaceutical Industries Ltd is Rated Hold

2026-09-15 10:10:51

Sun Pharmaceutical Industries Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 03 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

P/E at 34.98 vs Industry's 37.05: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-09-15 09:21:08

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers considerable prestige and market influence on Sun Pharmaceutical Industries Ltd. This membership not only reflects the company’s substantial market capitalisation—currently standing at ₹4,41,958 crores, categorising it firmly as a large-cap stock—but also ensures heightened visibility among domestic and global investors. Index inclusion typically drives consistent demand from passive funds and exchange-traded funds (ETFs) tracking the Nifty 50, thereby supporting liquidity and price stability.

Sun Pharma’s position within this elite group also means its stock movements can significantly impact the overall index performance, especially given the Ph...

Read full news article

P/E at 35.4 vs Industry's 37.05: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-09-11 09:21:05

Valuation Picture: A Slight Discount in a High-P/E Sector

The pharmaceutical sector currently trades at an average P/E of 37.05, reflecting elevated investor expectations amid ongoing innovation and regulatory approvals. Against this backdrop, Sun Pharmaceutical Industries Ltd’s P/E of 35.4 represents a 4.5% discount to the sector average. This valuation gap is relatively narrow but noteworthy given the company’s large-cap status and market leadership. The premium or discount relative to peers often signals market sentiment about growth prospects and risk profile — Read full news article

View All News